Jasper Therapeutics, Inc. (JSPR) · Oct 15, 2026 · Other events
IgAN enrollment complete — 18 patients enrolled; interim data expected by year-end 2026
Jasper Therapeutics completes IgAN enrollment for KP104 and accelerates its FSGS cohort, but the real test remains year-end interim data.
Jasper is rebuilding around Kira’s complement pipeline, with KP-104 now its lead renal-development asset. Following the July 2026 merger, management identified KP-104 as a Phase 2/3-ready program in PNH and high-unmet-need nephrology, with Stage 1 renal data already expected in the fourth quarter of 2026; the August financing was intended to fund planned operations through the second half of 2028. This filing advances that story operationally, not clinically. Jasper completed enrollment of the first IgAN cohort, with 18 patients spread across three maintenance-dosing schedules. The milestone puts the company in position to generate its first renal proof-of-concept signal, but it provides no new efficacy or safety readout. The incremental surprise is the expansion pace. Jasper says enrollment was completed on schedule and that initiation of the FSGS cohort has been accelerated, with first dosing anticipated in the first quarter of 2027. 〔0〕 Because the prior corporate update already pointed to interim renal data in the fourth quarter, this is partly a confirmation rather than a wholesale change in expectations. The key catalyst is now clearly defined. The company expects initial interim IgAN data by year-end 2026. 〔1〕 That result—not enrollment completion—will determine whether KP-104’s dual-complement rationale translates into a meaningful clinical signal. Bottom line: This modestly strengthens Jasper’s execution story and broadens the renal program, but the business remains dependent on the pending IgAN data rather than today’s enrollment milestone.
IgAN interim data by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!